Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates
Key Highlights
- ➤$1,037.6 million cash, equivalents and securities funds operations into mid-2028
- ➤Ribupatide injection Phase 2b fully enrolled; data anticipated mid-2027
- ➤Ribupatide oral global Phase 3 expected to begin in first half of 2027
- ➤Safiglipron Phase 2 fully enrolled; data anticipated in mid-2027
- ➤Net loss widened to $95.7 million from $39.6 million year over year
Expert Statements
Ron Renaud, President and Chief Executive Officer of Kailera
“Kailera was built to bring new medicines to people living with obesity, and our strong execution this quarter reflects that commitment. All four of our product candidates are on track to deliver important clinical milestones in 2027, including the initiation of our Phase 3 trial for ribupatide oral and the data readout from the ribupatide injection high-dose Phase 2b trial. With the ribupatide franchise’s category-leading potential at the core of a diversified portfolio, and a balance sheet that supports multiple value-creating inflection points into mid-2028, I am proud of our team and energized by what we aim to deliver for people living with obesity.”
* Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA * Ribupatide injection Phase 2b trial and KaiNETIC global Phase 3 program fully enrolled; data expected mid-2027 and mid-2028, respectively * Safiglipron (KAI-7535) global Phase 2 trial fully enrolled; data now anticipated mid-2027 * KAI-4729 IND now active with U.S. FDA; on track to initiate Phase 1 single-dose injection site/ethnic bridging trial by the end of 2026 * Cash continues to support execution of multiple clinical milestones with runway into mid-2028 WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today reported financial results for the third quarter ended September 30, 2026, and provided a summary of recent business highlights.
Get started
Create a free account to read the full story.